Market Research Report
Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products
|Published by||BCC Research||Product code||210214|
|Published||Content info||219 Pages
Delivery time: 1-2 business days
|Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products|
|Published: September 19, 2018||Content info: 219 Pages||
The global market for healthcare-acquired infection (HCAI) control should grow from $18.9 billion in 2018 to $24.7 billion by 2023 at a compound annual growth rate (CAGR) of 5.4% from 2018 through 2023.
The global market for environment sterilization in HCAI control should grow from $9.0 billion in 2018 to $12.4 billion by 2023 at a CAGR of 6.8% from 2018 through 2023.
The global market for pharmaceuticals in HCAI control should grow from $5.6 billion in 2018 to nearly $7.0 billion by 2023 at a CAGR of 4.3% from 2018 through 2023.
The report focuses on select drugs (antimicrobials), environment treatment (disinfectants, sterilization systems etc.) and provisions in medical devices (e.g. catheters, patient ventilation devices, sterile IV filters) that prevent occurrence of nosocomial infections.
Within each type of treatment, regional analyses will focus on the Americas (i.e. Canada, the U.S., Mexico, Central America and South America), EMRA (i.e. Europe, the Middle East, Russia and Africa) and Asia-Pacific (i.e. Japan, China, India, other Western Pacific countries such as Australia and New Zealand and other Southeast Asian countries).